首页> 外文期刊>Cancer control : >Non-myeloablative allogeneic stem cell transplantation: a new treatment option for acquired angioedema?
【24h】

Non-myeloablative allogeneic stem cell transplantation: a new treatment option for acquired angioedema?

机译:非清髓性同种异体干细胞移植:获得性血管性水肿的新治疗选择?

获取原文
           

摘要

Introduction: Acquired angioedema is a rare disorder causing recurrent life-threatening angioedema, due to decreased activity of C1 esterase inhibitor. Case report: A 57-year-old man presented to our hospital with recurrent swelling of the hands, lips, tongue, scrotum and throat. Lab examination showed the presence of an IgM kappa monoclonal antibody. Additional analysis showed that in the IgM fraction autoantibody activity against C1 esterase inhibitor was present. This confirmed the diagnosis of acquired angioedema in the presence of lymphoplasmacytic lymphoma. Despite standard therapy, there was an increase in the episodes of laryngeal oedema. Therefore it was decided to perform a non-myeloablative allogeneic haematopoietic stem cell transplantation, with his HLA-identical brother as donor. The post-transplantation course was without complications. Five years following alloSCT he is in complete remission without symptoms and with increased C1 esterase inhibitor activity. Discussion: In this case all other known treatment options for severe acquired angioedema failed. This is the first case describing treatment of severe acquired angioedema, caused by lymphoplasmacytic lymphoma, with an alloSCT.
机译:简介:获得性血管水肿是一种罕见的疾病,由于C1酯酶抑制剂的活性降低,会导致复发性危及生命的血管性水肿。病例报告:一名57岁的男子因手,嘴唇,舌头,阴囊和喉咙反复肿胀到我院就诊。实验室检查表明存在IgMκ单克隆抗体。进一步的分析表明,在IgM级分中,存在针对C1酯酶抑制剂的自身抗体活性。这证实了在存在淋巴浆细胞性淋巴瘤的情况下对获得性血管性水肿的诊断。尽管采用标准疗法,但喉头水肿的发生率有所增加。因此,决定以其HLA相同的兄弟作为供体进行非清髓性异基因造血干细胞移植。移植后的过程没有并发症。 alloSCT后五年,他完全缓解,没有症状,并且C1酯酶抑制剂活性增加。讨论:在这种情况下,所有其他已知的严重后天性血管性水肿的治疗选择均无效。这是第一个用alloSCT描述由淋巴浆细胞性淋巴瘤引起的严重获得性血管性水肿的病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号